ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 140 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $2,304,792 | +14.5% | 241,846 | +32.1% | 0.00% | 0.0% |
Q1 2023 | $2,013,165 | -18.2% | 183,015 | +10.0% | 0.00% | 0.0% |
Q4 2022 | $2,462,395 | -2.4% | 166,378 | +26.1% | 0.00% | -33.3% |
Q3 2022 | $2,522,000 | -13.4% | 131,979 | -3.5% | 0.00% | 0.0% |
Q2 2022 | $2,913,000 | +17.0% | 136,724 | +5.8% | 0.00% | +50.0% |
Q1 2022 | $2,490,000 | -1.7% | 129,276 | +5.9% | 0.00% | 0.0% |
Q4 2021 | $2,532,000 | -13.2% | 122,097 | +0.0% | 0.00% | -33.3% |
Q3 2021 | $2,916,000 | -11.7% | 122,087 | +0.7% | 0.00% | 0.0% |
Q2 2021 | $3,304,000 | -4.6% | 121,216 | +1.3% | 0.00% | 0.0% |
Q1 2021 | $3,462,000 | – | 119,670 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
Two Seas Capital LP | 164,807 | $875,125 | 0.18% |